Abstract
Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
CNS & Neurological Disorders - Drug Targets
Title: Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
Volume: 10 Issue: 4
Author(s): Junpeng Zhao and Qunyuan Xu
Affiliation:
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
Abstract: Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Export Options
About this article
Cite this article as:
Zhao Junpeng and Xu Qunyuan, Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells, CNS & Neurological Disorders - Drug Targets 2011; 10(4) . https://dx.doi.org/10.2174/187152711795563921
DOI https://dx.doi.org/10.2174/187152711795563921 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?
Current Molecular Pharmacology Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Support of Neurorehabilitation
Current Drug Therapy